SRC and Familial prostate cancer: Since CTA095 induces a significant amount of caspase activation and apoptosis in prostate cancer cells, which is different from the Src inhibitor AZD0530, we asked whether CTA095 could enhance the efficacy of Src inhibitors, and whether it could overcome prostate cancer cell resistance developed toward this Src inhibitor.